Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1/PHASE2
25 participants
INTERVENTIONAL
2005-09-30
2008-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nicotinamide and Glaucoma
NCT05916066
Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study
NCT05695027
Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients
NCT06991712
Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin
NCT04784234
Glaucoma Eye Drop Instillation: Impact of Education
NCT01416415
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vitamins, minerals and medical herbs
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Above the age of 50 years and have severe damage that does not progress to the vision field in the upper and lower half. Scoring of the vision field will be made according to the Agis study instructions.
Exclusion Criteria
* Allergy to one of the components in the preparation
* Deterioration in the vision field in the last year
* Kidney diseases, gastrointestinal (G.I.) tract, liver diseases, coagulation problems and thyroid diseases
* Persons who take steroids
* Diabetics or unbalanced hyperglycemia
* Autoimmune diseases
* Hypertension (not responding to treatment)
* Psychiatric treatment with drugs, psychiatric pathologies
* Pregnancy
* Ability to take more than 3 pills per day regularly
* Smoking
40 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Future Products Management
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Future Products Management
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Meir Gorban, MD
Role: STUDY_DIRECTOR
Future Products Management
Hani Levkovitch-Verbin, MD
Role: PRINCIPAL_INVESTIGATOR
Sheba Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sheba Medical Center
Tel Litwinsky, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
g88
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.